Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Prepaid Assets (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Prepaid Assets data on record, last reported at $2.5 million in Q4 2025.

  • For Q4 2025, Prepaid Assets fell 2.7% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $2.5 million, down 2.7%, while the annual FY2025 figure was $2.5 million, 2.7% down from the prior year.
  • Prepaid Assets reached $2.5 million in Q4 2025 per LCTX's latest filing, up from $1.6 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $3.2 million in Q3 2021 and bottomed at $1.3 million in Q3 2024.
  • Average Prepaid Assets over 5 years is $2.0 million, with a median of $1.9 million recorded in 2025.
  • Peak YoY movement for Prepaid Assets: skyrocketed 123.55% in 2021, then crashed 48.54% in 2022.
  • A 5-year view of Prepaid Assets shows it stood at $3.2 million in 2021, then tumbled by 42.17% to $1.8 million in 2022, then rose by 20.57% to $2.2 million in 2023, then increased by 15.88% to $2.6 million in 2024, then decreased by 2.7% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Prepaid Assets were $2.5 million in Q4 2025, $1.6 million in Q3 2025, and $1.3 million in Q2 2025.